Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies

Open access

Abstract

Many patients with developmental and epileptic encephalopathies present with variants in genes coding for GABA A receptors. These variants are presumed to cause loss-of-function receptors leading to reduced neuronal GABAergic activity. Yet, patients with GABA A receptor variants have diverse clinical phenotypes and many are refractory to treatment despite the availability of drugs that enhance GABAergic activity. Here we show that 44 pathogenic GABRB3 missense variants segregate into gain-of-function and loss-of-function groups and respective patients display distinct clinical phenotypes. The gain-of-function cohort ( n = 27 patients) presented with a younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom in response to treatment. Febrile seizures at onset are exclusive to the loss-of-function cohort ( n = 47 patients). Overall, patients with GABRB3 variants that increase GABAergic activity have more severe developmental and epileptic encephalopathies. This paradoxical finding challenges our current understanding of the GABAergic system in epilepsy and how patients should be treated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29280-x

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GABRB3 epilepsy-associated variants. a Two-dimensional representation (top) of a GABAA receptor β3 subunit (pdb:6hup)15 highlighting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange). Dots represent individual variants associated with DEE. b 3D cartoon structure of the pentameric α1β3γ2 GABAA receptor from above and the side. α1 (pale green) β3 (silver) and γ2 (light purple) subunits are colour coded and the GABA molecule is represented as black sticks. A 3D cartoon structure of a β3 subunit showing the location of variants as spheres coloured by their location in the binding loops (blue), coupling loops (pink), transmembrane regions (orange) or elsewhere (dark grey). c The GABRB3 sequence is shown with missense amino acid variants numbered and in bold. Structural features of the binding, coupling loops and transmembrane regions are coloured.
Fig. 1 GABRB3 epilepsy-associated variants. a Two-dimensional representation (top) of a GABAA receptor β3 subunit (pdb:6hup)15 highlighting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange). Dots represent individual variants associated with DEE. b 3D cartoon structure of the pentameric α1β3γ2 GABAA receptor from above and the side. α1 (pale green) β3 (silver) and γ2 (light purple) subunits are colour coded and the GABA molecule is represented as black sticks. A 3D cartoon structure of a β3 subunit showing the location of variants as spheres coloured by their location in the binding loops (blue), coupling loops (pink), transmembrane regions (orange) or elsewhere (dark grey). c The GABRB3 sequence is shown with missense amino acid variants numbered and in bold. Structural features of the binding, coupling loops and transmembrane regions are coloured.CC BY · PubMed Central
Fig. 2 Functional evaluation of GABRB3 missense variants. a Concatenated receptor design showing the γ2-β3-α1-β3-α1 DNA construct used to introduce single missense variants. A pentameric receptor that arranges with a single β3 variant (star) is depicted. b Raw electrophysiological recordings and concentration–response curves at selected concatenated γ2-β3-α1-β3-α1 wild-type (black), p.(Leu284Pro) (blue) and p.(Tyr302Cys) (red) β3 variant receptors that represent a gain-of-function and a loss-of-function variant, respectively. Bars indicate GABA applications and scale bars for each trace are shown. Peak current amplitudes were measured at each GABA concentration and a Hill equation was fitted to the data. Thereafter the dataset was normalized to its respective maximum current amplitude for each cell. Black circles (wild-type, n = 12 independent cells), blue open squares (p.(Leu284Pro), n = 12) and red open circles (p.(Tyr302Cys), n = 12) represent the mean ± s.d (n ≥ 12) and the lines represent the fitted Hill equation at each receptor. Gain-of-function variants shift the concentration–response curve to the left, loss-of-function to the right. Source data are provided in the Source Data file.
Fig. 2 Functional evaluation of GABRB3 missense variants. a Concatenated receptor design showing the γ2-β3-α1-β3-α1 DNA construct used to introduce single missense variants. A pentameric receptor that arranges with a single β3 variant (star) is depicted. b Raw electrophysiological recordings and concentration–response curves at selected concatenated γ2-β3-α1-β3-α1 wild-type (black), p.(Leu284Pro) (blue) and p.(Tyr302Cys) (red) β3 variant receptors that represent a gain-of-function and a loss-of-function variant, respectively. Bars indicate GABA applications and scale bars for each trace are shown. Peak current amplitudes were measured at each GABA concentration and a Hill equation was fitted to the data. Thereafter the dataset was normalized to its respective maximum current amplitude for each cell. Black circles (wild-type, n = 12 independent cells), blue open squares (p.(Leu284Pro), n = 12) and red open circles (p.(Tyr302Cys), n = 12) represent the mean ± s.d (n ≥ 12) and the lines represent the fitted Hill equation at each receptor. Gain-of-function variants shift the concentration–response curve to the left, loss-of-function to the right. Source data are provided in the Source Data file.CC BY · PubMed Central
Fig. 3 Changes in GABA sensitivity and maximum currents of GABRB3 missense variants. A two-dimensional representation (top) of a GABAA receptor β3 subunit depicting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange) is shown. Bar graph summarizing the fold-shift in GABA sensitivity (mean ΔlogEC50 ± s.d.) and maximum current (mean Imax ± s.d.) for each variant according to their amino acid residue. At GABA sensitivity, blue bars indicate variants that have significantly increased the GABA sensitivity with the direction of the bars upwards, red bars indicate variants that have significantly decreased the GABA sensitivity with the direction of the bars downwards and grey bars indicate no significant change. Significance was determined by one-way ANOVA (F (53, 725) = 355.5) and multiple comparisons with corrected Dunnett’s post-hoc test (p < 0.0001, n = 135 independent cells (wild-type); 10 (G32R, M80T, R142L, A305T, A305V, I306T); 11 (E77K, M80K, D120N, T157M, Y182F, Y184H, Q249K, S254F, L256Q, T281I, L284M, T287I, T288N, L293H, P301L); 12 (S76C, V78F, L124F, L170R, E180G, F225C, Y230H, Y245H, P253L, I280F, L284R, L284P, Y302C, F318S, N328D, E357K, S420I, R429Q, S433L); 13 (E178G, T185I); 14 (K127R, L165Q, Q210H, R232Q, T281A); 15 (V37G, N110D, ins138_139H, R166S, I300T); 17 (L310I). At maximum current, grey bars indicate no significant change and red bars indicate significantly reduced maximum currents. Significance was determined by one-way Kruskal–Willis ANOVA (H(55, 1653) = 674.4) and multiple comparisons with corrected Dunn’s post-hoc test (p < 0.0001, n = 256 independent cells (wild-type); 22 (R232P, L284R, I300T, Y302); 23 (D120N, L124F, L284, P301L, A305T); 24 (E77K, V78F, M80K, K127R, L165Q, Q210H, R232Q, Y245H, P253L, S254F, L256Q, I280F, T281A, T281I, L284M, T287I, T288N, L293H, A305V, I306T); 26 (M80T, Y184H, Q249K); 27 (G32R, S76C, R142L, L170R, E180G, Y182F); 28 (L310I); 29 (F318S, E357K, R429Q, S433L); 30 (ins138_139H, Q210H); 33 (V37G), p.(R166S); 36 (S420Ile); 39 (N328D). Individual data points are in the supplementary information (Supplementary Fig S2). Source data are provided in the Source Data file.
Fig. 3 Changes in GABA sensitivity and maximum currents of GABRB3 missense variants. A two-dimensional representation (top) of a GABAA receptor β3 subunit depicting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange) is shown. Bar graph summarizing the fold-shift in GABA sensitivity (mean ΔlogEC50 ± s.d.) and maximum current (mean Imax ± s.d.) for each variant according to their amino acid residue. At GABA sensitivity, blue bars indicate variants that have significantly increased the GABA sensitivity with the direction of the bars upwards, red bars indicate variants that have significantly decreased the GABA sensitivity with the direction of the bars downwards and grey bars indicate no significant change. Significance was determined by one-way ANOVA (F (53, 725) = 355.5) and multiple comparisons with corrected Dunnett’s post-hoc test (p < 0.0001, n = 135 independent cells (wild-type); 10 (G32R, M80T, R142L, A305T, A305V, I306T); 11 (E77K, M80K, D120N, T157M, Y182F, Y184H, Q249K, S254F, L256Q, T281I, L284M, T287I, T288N, L293H, P301L); 12 (S76C, V78F, L124F, L170R, E180G, F225C, Y230H, Y245H, P253L, I280F, L284R, L284P, Y302C, F318S, N328D, E357K, S420I, R429Q, S433L); 13 (E178G, T185I); 14 (K127R, L165Q, Q210H, R232Q, T281A); 15 (V37G, N110D, ins138_139H, R166S, I300T); 17 (L310I). At maximum current, grey bars indicate no significant change and red bars indicate significantly reduced maximum currents. Significance was determined by one-way Kruskal–Willis ANOVA (H(55, 1653) = 674.4) and multiple comparisons with corrected Dunn’s post-hoc test (p < 0.0001, n = 256 independent cells (wild-type); 22 (R232P, L284R, I300T, Y302); 23 (D120N, L124F, L284, P301L, A305T); 24 (E77K, V78F, M80K, K127R, L165Q, Q210H, R232Q, Y245H, P253L, S254F, L256Q, I280F, T281A, T281I, L284M, T287I, T288N, L293H, A305V, I306T); 26 (M80T, Y184H, Q249K); 27 (G32R, S76C, R142L, L170R, E180G, Y182F); 28 (L310I); 29 (F318S, E357K, R429Q, S433L); 30 (ins138_139H, Q210H); 33 (V37G), p.(R166S); 36 (S420Ile); 39 (N328D). Individual data points are in the supplementary information (Supplementary Fig S2). Source data are provided in the Source Data file.CC BY · PubMed Central
Fig. 4 Clinical features of patients harbouring a LOF or GOF GABRB3 variant. a Violin plot of age of seizure onset at gain-of-function (blue; n = 21 patients) and loss-of-function (red; n = 43 patients) variants. Dots represent individual data points, dotted lines represent median and quartiles. Two-sided unpaired Mann–Whitney U test, p = 1.1 × 10−11, U = 39). b Selected seizure types reported at onset for patients with gain-of-function (blue bars) and loss-of-function (red bars) variants. Percentage of patients reporting each seizure type is shown. c Odds ratio of key clinical outcomes in gain-of-function vs. loss-of-function variants with the centre circle showing the log10 odds ratio and 95 % confidence interval. Blue indicates significant enrichment in gain-of-function variants, and red indicates significant enrichment in the loss-of-function variants. For each indication, the total number of patients reporting were n = 18, 27, 27, 16, 11 and 19 gain-of-function patients, and n = 40, 47, 47, 27, 24 and 36 loss-of-function patients for severe intellectual disability, febrile seizures, focal seizures, hypotonia, microcephaly and seizure freedom, respectively. Fisher’s exact test, two-sided, p = 2.7 × 10−8, 2 × 10−5, 0.019, 3.5 × 10−7, 3 × 10−4 and 0.013, respectively. d Selected seizure types reported at follow-up for patients with a gain-of-function (blue bars) and loss-of-function (red bars) variants. Percentage of patients reporting each seizure type is shown. Source data are provided in the supplementary information (Supplementary Table S1).
Fig. 4 Clinical features of patients harbouring a LOF or GOF GABRB3 variant. a Violin plot of age of seizure onset at gain-of-function (blue; n = 21 patients) and loss-of-function (red; n = 43 patients) variants. Dots represent individual data points, dotted lines represent median and quartiles. Two-sided unpaired Mann–Whitney U test, p = 1.1 × 10−11, U = 39). b Selected seizure types reported at onset for patients with gain-of-function (blue bars) and loss-of-function (red bars) variants. Percentage of patients reporting each seizure type is shown. c Odds ratio of key clinical outcomes in gain-of-function vs. loss-of-function variants with the centre circle showing the log10 odds ratio and 95 % confidence interval. Blue indicates significant enrichment in gain-of-function variants, and red indicates significant enrichment in the loss-of-function variants. For each indication, the total number of patients reporting were n = 18, 27, 27, 16, 11 and 19 gain-of-function patients, and n = 40, 47, 47, 27, 24 and 36 loss-of-function patients for severe intellectual disability, febrile seizures, focal seizures, hypotonia, microcephaly and seizure freedom, respectively. Fisher’s exact test, two-sided, p = 2.7 × 10−8, 2 × 10−5, 0.019, 3.5 × 10−7, 3 × 10−4 and 0.013, respectively. d Selected seizure types reported at follow-up for patients with a gain-of-function (blue bars) and loss-of-function (red bars) variants. Percentage of patients reporting each seizure type is shown. Source data are provided in the supplementary information (Supplementary Table S1).CC BY · PubMed Central
Fig. 5 Representative electroencepholagram from patients harbouring a GOF or LOF variant. Interictal EEG showed a disorganized background activity with intermixed 12–15 Hz component (blue boxes) and multifocal epileptiform abnormalities (red circles) in patients with gain-of-function variants and normal/slightly delayed background activity, with generalized high amplitude 3–4 Hz activity/spike and slow waves (dotted lines) in patients with loss-of-function variants.
Fig. 5 Representative electroencepholagram from patients harbouring a GOF or LOF variant. Interictal EEG showed a disorganized background activity with intermixed 12–15 Hz component (blue boxes) and multifocal epileptiform abnormalities (red circles) in patients with gain-of-function variants and normal/slightly delayed background activity, with generalized high amplitude 3–4 Hz activity/spike and slow waves (dotted lines) in patients with loss-of-function variants.CC BY · PubMed Central
Fig. 6 2D structural map of pathogenic and benign missense GABRB3 variants. a, b Two-dimensional representation of a GABAA receptor β3 subunit depicting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange) is shown with a row of black dots indicating the location of benign variants in the gnomAD database. The upper row of dots indicates pathogenic or likely pathogenic GOF (blue), LOF (red) variants, benign or likely benign (grey) variants and VUS (white) variants. Source data are provided in the Source Data file.
Fig. 6 2D structural map of pathogenic and benign missense GABRB3 variants. a, b Two-dimensional representation of a GABAA receptor β3 subunit depicting binding loops (blue), coupling loops (pink) and four transmembrane regions (orange) is shown with a row of black dots indicating the location of benign variants in the gnomAD database. The upper row of dots indicates pathogenic or likely pathogenic GOF (blue), LOF (red) variants, benign or likely benign (grey) variants and VUS (white) variants. Source data are provided in the Source Data file.CC BY · PubMed Central
Fig. 7 3D structural map and concentration–response curves. 3D structure of GABAA receptor β3 subunit displaying the location of: gain-of-function (blue), loss-of-function (red) and dual (purple) variants, with the variants showing no functional change in grey. a–e Structure of the β3 subunit with the backbone coloured in grey and a close-up view of residues a directly binding GABA; b in the outer shell of GABA binding; c β1-2 coupling loop; d M2-M3 coupling loop and e M2 region with amino acid sidechains of residues containing variants in sticks. Red indicates loss-of-function, blue indicates gain-of-function variants and GABA is in black. Concentration–response curves for variants directly binding GABA. Dots represent mean ± s.d. and lines the fitted Hill equation. Wild-type concentration–response curves run on the same days as the variants are shown in black. Red indicates loss-of-function and blue indicates gain. For each panel, a n = 35, 12, 11, 12, 12 independent experiments at wild-type, E180G, Y182F, F225C, Y230H; b n = 34, 11, 12, 14, 13, 11, 13, 14 at wild-type, D120N, L124F, K127R, E178G, Y184H, T185I, R232Q; c n = 34, 12, 11, 12, 11, 10 at wild-type, S76C, E77K, V78F, M80K, M80T; d n = 36, 15, 11, 12, 10, 10, 24 at wild-type, I300T, P301L, Y302C, A305T, A305V, I306T; e n = 57, 12, 14, 11, 11, 12, 12, 11, 11, 11 at wild-type, I280F, T281A, T281I, L284M, L284P, L284R, T287I, T288N, L293H. Source data are provided in the Source Data file.
Fig. 7 3D structural map and concentration–response curves. 3D structure of GABAA receptor β3 subunit displaying the location of: gain-of-function (blue), loss-of-function (red) and dual (purple) variants, with the variants showing no functional change in grey. a–e Structure of the β3 subunit with the backbone coloured in grey and a close-up view of residues a directly binding GABA; b in the outer shell of GABA binding; c β1-2 coupling loop; d M2-M3 coupling loop and e M2 region with amino acid sidechains of residues containing variants in sticks. Red indicates loss-of-function, blue indicates gain-of-function variants and GABA is in black. Concentration–response curves for variants directly binding GABA. Dots represent mean ± s.d. and lines the fitted Hill equation. Wild-type concentration–response curves run on the same days as the variants are shown in black. Red indicates loss-of-function and blue indicates gain. For each panel, a n = 35, 12, 11, 12, 12 independent experiments at wild-type, E180G, Y182F, F225C, Y230H; b n = 34, 11, 12, 14, 13, 11, 13, 14 at wild-type, D120N, L124F, K127R, E178G, Y184H, T185I, R232Q; c n = 34, 12, 11, 12, 11, 10 at wild-type, S76C, E77K, V78F, M80K, M80T; d n = 36, 15, 11, 12, 10, 10, 24 at wild-type, I300T, P301L, Y302C, A305T, A305V, I306T; e n = 57, 12, 14, 11, 11, 12, 12, 11, 11, 11 at wild-type, I280F, T281A, T281I, L284M, L284P, L284R, T287I, T288N, L293H. Source data are provided in the Source Data file.CC BY · PubMed Central
Fig. 8 Flowchart for predicting LOF and GOF GABRB3 variants based on clinical indicators. When a GABRB3 missense variant is identified, there are several clinical features that can help predict whether the variant is LOF or GOF. Key features of LOF variants include an age of onset of 6 months or older and the presence of febrile seizures. Supporting features include a lack of hypotonia and microcephaly. As patients develop, LOF variants typically result in generalised seizures (includes atonic, myoclonic and bilateral tonic-to-clonic seizures), EEG with generalised interictal epileptiform discharges (IEDs) and ID in the normal or mild to moderate spectrum. For GOF variants, key features are focal seizures that present at an age of onset less than 6 months, and supporting features include hypotonia and microcephaly. As the patient ages, GOF variants feature focal seizures, EEG with multifocal interictal epileptiform discharges, and severe ID. If the patient presentation has a mixture of these indications, functional testing of the variant is needed to determine whether it has LOF or GOF traits. p-values comparing the clinical indicators for patients with LOF and GOF variants are included (also see Fig. 4).
Fig. 8 Flowchart for predicting LOF and GOF GABRB3 variants based on clinical indicators. When a GABRB3 missense variant is identified, there are several clinical features that can help predict whether the variant is LOF or GOF. Key features of LOF variants include an age of onset of 6 months or older and the presence of febrile seizures. Supporting features include a lack of hypotonia and microcephaly. As patients develop, LOF variants typically result in generalised seizures (includes atonic, myoclonic and bilateral tonic-to-clonic seizures), EEG with generalised interictal epileptiform discharges (IEDs) and ID in the normal or mild to moderate spectrum. For GOF variants, key features are focal seizures that present at an age of onset less than 6 months, and supporting features include hypotonia and microcephaly. As the patient ages, GOF variants feature focal seizures, EEG with multifocal interictal epileptiform discharges, and severe ID. If the patient presentation has a mixture of these indications, functional testing of the variant is needed to determine whether it has LOF or GOF traits. p-values comparing the clinical indicators for patients with LOF and GOF variants are included (also see Fig. 4).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 93

Metadata

Authors
Absalom, N. L., Liao, V. W. Y., Johannesen, K. M. H., Gardella, E., Jacobs, J., Lesca, G., Gokce-Samar, Z., Arzimanoglou, A., Zeidler, S., Striano, P., Meyer, P., Benkel-Herrenbrueck, I., Mero, I.-L., Rummel, J., Chebib, M., Møller, R. S., & Ahring, P. K.
Affiliations
  • The University of Sydney (AU)
  • University of Southern Denmark (DK)
  • University of Freiburg (DE)
  • Hospices Civils de Lyon (FR)
  • Erasmus MC (NL)
  • Istituto Giannina Gaslini (IT)
  • Inserm (FR)
  • Heinrich Heine University Düsseldorf (DE)
  • Oslo University Hospital (NO)
Corresponding author
  • Møller, Rikke S.
  • Ahring, Philip K.
Venue
Nature Communications
Published
2022-04-05
Volume
13
Issue
1
Pages
1822-1822
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4223515850
Cited by
89
References
53
Citations by year
2026: 21 · 2025: 21 · 2024: 18 · 2023: 21 · 2022: 8
FWCI
11.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
Funders
  • Lundbeckfonden (R324-2019-1083)
  • Novo Nordisk
  • Novo Nordisk Fonden (NNF19OC0058749)
  • H. Lundbeck A/S
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
GABRB3, GABAA receptor, developmental and epileptic encephalopathy, gain-of-function mutations, loss-of-function mutations, missense mutations, febrile seizures, intellectual disability, focal seizures, hypotonia, GABAergic system, epilepsy genetics
MeSH terms
Loss of Function Mutation, Gain of Function Mutation, Epilepsy, Humans, Phenotype, Receptors, GABA-A, Seizures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. https://app.cochat.ai/papers/10.1038/s41467-022-29280-x
The paper
Absalom, N. L., Liao, V. W. Y., Johannesen, K. M. H., Gardella, E., Jacobs, J., Lesca, G., Gokce-Samar, Z., Arzimanoglou, A., Zeidler, S., Striano, P., Meyer, P., Benkel-Herrenbrueck, I., Mero, I.-L., Rummel, J., Chebib, M., Møller, R. S., & Ahring, P. K. (2022). Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nature Communications. https://doi.org/10.1038/s41467-022-29280-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.